Scott Bickel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott Bickel has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Nemr Eid
Norton Children’s Pulmonology, Affiliated with the University of Louisville School of Medicine, Louisville, USA
12 shared publicationsRonald Morton
Department of Pediatrics, Division of Pulmonology, Allergy and Immunology, University of Louisville, Norton Children's and University of Louisville School of Medicine, Louisville, Kentucky, USA
9 shared publicationsAdrian O'Hagan
Division of Pediatric Pulmonology, Norton Children's and University of Louisville School of Medicine, Louisville, KY
4 shared publications- Ronald Morton
Norton Children’s Pulmonology, Affiliated with the University of Louisville School of Medicine, Louisville, USA
3 shared publications - Andrea L. Behrman
UofL Health, Frazier Rehab Institute, Kosair Charities Center for Pediatric NeuroRecovery, Louisville, KY, United States
2 shared publications Caitlin Canal
Department of Pediatrics, Witham Health Services, Lebanon, IN
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
A prospective observational pilot study assessing childhood asthma control in areas with increased urban environmental greenery
The purpose of this study is to assess the feasibility of measuring differences in asthma symptoms, lung function, asthma biomarkers, and allergic sensitiz
- 28 May 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessA prospective observational pilot study assessing childhood asthma control in areas with increased urban environmental greenery
The purpose of this study is to assess the feasibility of measuring differences in asthma symptoms, lung function, asthma biomarkers, and allergic sensitiz
- Open Access
- 28 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (2) , 231-238
Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
Children with asthma and obesity are more likely to have lower vitamin D levels, but the optimal replacement dose is unknown in this population. The objective of this study is identifying a vitamin D dose in children with obesity‐related asthma that safely achieves serum vitamin D levels of ≥ 40 ng/mL. This prospective multisite randomized controlled trial recruited children/adolescents with asthma and body mass index ≥ 85% for age/sex. Part 1 (dose finding), evaluated 4 oral vitamin D regimens for 16 weeks to identify a replacement dose that achieved serum vitamin D levels ≥ 40 ng/mL. Part 2 compared the replacement dose calculated from part 1 (50,000 IU loading dose with 8,000 IU daily) to standard of care (SOC) for 16 weeks to identify the proportion of children achieving target serum 25(OH)D level. Part 1 included 48 randomized participants. Part 2 included 64 participants. In Part 1, no SOC participants achieved target serum level, but 50–72.7% of participants in cohorts A‐C achieved the target serum level. In part 2, 78.6% of replacement dose participants achieved target serum level compared with none in the SOC arm. No related serious adverse events were reported. This trial confirmed a 50,000 IU loading dose plus 8,000 IU daily oral vitamin D as safe and effective in increasing serum 25(OH)D levels in children/adolescents with overweight/obesity to levels ≥ 40 ng/mL. Given the critical role of vitamin D in many conditions complicating childhood obesity, these data close a critical gap in our understanding of vitamin D dosing in children.
- 28 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (2) , 231-238
Open AccessVitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial
Children with asthma and obesity are more likely to have lower vitamin D levels, but the optimal replacement dose is unknown in this population. The objective of this study is identifying a vitamin D dose in children with obesity‐related asthma that safely achieves serum vitamin D levels of ≥ 40 ng/mL. This prospective multisite randomized controlled trial recruited children/adolescents with asthma and body mass index ≥ 85% for age/sex. Part 1 (dose finding), evaluated 4 oral vitamin D regimens for 16 weeks to identify a replacement dose that achieved serum vitamin D levels ≥ 40 ng/mL. Part 2 compared the replacement dose calculated from part 1 (50,000 IU loading dose with 8,000 IU daily) to standard of care (SOC) for 16 weeks to identify the proportion of children achieving target serum 25(OH)D level. Part 1 included 48 randomized participants. Part 2 included 64 participants. In Part 1, no SOC participants achieved target serum level, but 50–72.7% of participants in cohorts A‐C achieved the target serum level. In part 2, 78.6% of replacement dose participants achieved target serum level compared with none in the SOC arm. No related serious adverse events were reported. This trial confirmed a 50,000 IU loading dose plus 8,000 IU daily oral vitamin D as safe and effective in increasing serum 25(OH)D levels in children/adolescents with overweight/obesity to levels ≥ 40 ng/mL. Given the critical role of vitamin D in many conditions complicating childhood obesity, these data close a critical gap in our understanding of vitamin D dosing in children.
- 16 June 2023
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 36 (2) , 37-40
New for 2022: Food and Drug Administration Approvals of Pediatric Respiratory Medications
Pediatric Allergy, Immunology, and Pulmonology
- 16 June 2023
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 36 (2) , 37-40
New for 2022: Food and Drug Administration Approvals of Pediatric Respiratory Medications
Pediatric Allergy, Immunology, and Pulmonology
- 13 December 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (7) , 1269-1279
Appropriate inhaler use in children with asthma: barriers and opportunities through the lens of the socio-ecological model
Objective: Proper use of inhaled medications is essential for management of asthma, as inhaled therapies are recommended as first-line for both prevention and treatment of asthma symptoms. Optimizing adherence requires identifying and understanding multiple layers of systemic complexity to obtaining and using these therapies and offering specific solutions to address these barriers. Bronfenbrenner’s socio-ecological model provides a framework for examining multilevel systems – both internal and external – that contribute to the management of childhood asthma. The four levels in this model consist of factors related to the individual, interpersonal relationships, organizational entities, and societal structures and rules. This narrative review identifies influences and factors related to asthma inhaler adherence by each level and offers evidence-based solutions to each obstacle. Data Sources: We conducted PubMed searches to identify relevant articles for barriers and solutions impacting asthma control at each level of the socio-ecological model. Study Selection: Common barriers to asthma control at each model level were identified. Pertinent studies for each barrier were identified and reviewed by the writing group for inclusion into the narrative review. Results: For each level of the socio-ecological model, three primary issues were identified based on the literature review. Approaches for addressing each issue in an evidence-based, systematic fashion are presented. Conclusion: Understanding the obstacles and potential interventions to achieve proper use of inhaled medications is a critical step necessary to develop and implement systematic solutions aimed at improving asthma control and morbidity for the more than 6 million affected children in the United States.
- 13 December 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (7) , 1269-1279
Appropriate inhaler use in children with asthma: barriers and opportunities through the lens of the socio-ecological model
Objective: Proper use of inhaled medications is essential for management of asthma, as inhaled therapies are recommended as first-line for both prevention and treatment of asthma symptoms. Optimizing adherence requires identifying and understanding multiple layers of systemic complexity to obtaining and using these therapies and offering specific solutions to address these barriers. Bronfenbrenner’s socio-ecological model provides a framework for examining multilevel systems – both internal and external – that contribute to the management of childhood asthma. The four levels in this model consist of factors related to the individual, interpersonal relationships, organizational entities, and societal structures and rules. This narrative review identifies influences and factors related to asthma inhaler adherence by each level and offers evidence-based solutions to each obstacle. Data Sources: We conducted PubMed searches to identify relevant articles for barriers and solutions impacting asthma control at each level of the socio-ecological model. Study Selection: Common barriers to asthma control at each model level were identified. Pertinent studies for each barrier were identified and reviewed by the writing group for inclusion into the narrative review. Results: For each level of the socio-ecological model, three primary issues were identified based on the literature review. Approaches for addressing each issue in an evidence-based, systematic fashion are presented. Conclusion: Understanding the obstacles and potential interventions to achieve proper use of inhaled medications is a critical step necessary to develop and implement systematic solutions aimed at improving asthma control and morbidity for the more than 6 million affected children in the United States.
- 16 September 2022
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 35 (3) , 111-113
Digital Inhaler Technology: Is It Ready for Prime Time?
Pediatric Allergy, Immunology, and Pulmonology
- 16 September 2022
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 35 (3) , 111-113
Digital Inhaler Technology: Is It Ready for Prime Time?
Pediatric Allergy, Immunology, and Pulmonology
- 27 May 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (9) , e403-e405
COVID-19 Disease in Children with Medical Complexity in a Pediatric Long-term Care Facility: A Case Series
- 27 May 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (9) , e403-e405
COVID-19 Disease in Children with Medical Complexity in a Pediatric Long-term Care Facility: A Case Series
- 16 June 2021
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 34 (2) , 43-45
Pulmonary Function Testing in the Coronavirus Disease Era: Lessons and Opportunities
Pediatric Allergy, Immunology, and Pulmonology
- 16 June 2021
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 34 (2) , 43-45
Pulmonary Function Testing in the Coronavirus Disease Era: Lessons and Opportunities
Pediatric Allergy, Immunology, and Pulmonology
- 9 March 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 234, 128-133.e1
Impact of Payor-Initiated Switching of Inhaled Corticosteroids on Lung Function
- 9 March 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 234, 128-133.e1
Impact of Payor-Initiated Switching of Inhaled Corticosteroids on Lung Function
- 1 March 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 285, 103604
Single and sequential voluntary cough in children with chronic spinal cord injury
- 1 March 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 285, 103604
Single and sequential voluntary cough in children with chronic spinal cord injury
- Open Access
Impact of Activity-Based Therapy on Respiratory Outcomes in a Medically Complex Child
Introduction: Activity-based therapies (ABTs) focus on activating the neuromuscular system below the level of spinal cord injury (SCI) promoting neuromuscular capacity. Case description: A 2 year 7 month old with history of prematurity at 29 weeks, neonatal epidural abscess, resultant cervical SCI, respiratory failure, and global developmental delays presented for enrollment in an outpatient activity-based therapy program. Upon presentation to this program, he required nighttime mechanical ventilation via tracheostomy and daytime suctioning. He could not perform any age-appropriate activities and was described by his mother as ‘present’, neither engaged nor attentive. During and after 7 months of participation in ABTs including locomotor training and neuromuscular electrical stimulation, the patient demonstrated unexpected changes in his respiratory status leading to ventilator weaning with concomitant improvements in head and trunk control, participation, development, and quality of life. Discussion: ABT was not only safe for a medically complex child, but also this intervention had a remarkable effect on unresolved respiratory capacity and a more widespread impact on other functions as well as development. A child with a chronic, severe SCI demonstrated positive and impactful improvements in health, functional status, and quality of life during an episode of ABT.
Open AccessImpact of Activity-Based Therapy on Respiratory Outcomes in a Medically Complex Child
Introduction: Activity-based therapies (ABTs) focus on activating the neuromuscular system below the level of spinal cord injury (SCI) promoting neuromuscular capacity. Case description: A 2 year 7 month old with history of prematurity at 29 weeks, neonatal epidural abscess, resultant cervical SCI, respiratory failure, and global developmental delays presented for enrollment in an outpatient activity-based therapy program. Upon presentation to this program, he required nighttime mechanical ventilation via tracheostomy and daytime suctioning. He could not perform any age-appropriate activities and was described by his mother as ‘present’, neither engaged nor attentive. During and after 7 months of participation in ABTs including locomotor training and neuromuscular electrical stimulation, the patient demonstrated unexpected changes in his respiratory status leading to ventilator weaning with concomitant improvements in head and trunk control, participation, development, and quality of life. Discussion: ABT was not only safe for a medically complex child, but also this intervention had a remarkable effect on unresolved respiratory capacity and a more widespread impact on other functions as well as development. A child with a chronic, severe SCI demonstrated positive and impactful improvements in health, functional status, and quality of life during an episode of ABT.